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Decreased blood flow in the brain leads to a rapid increase in reactive oxygen species (ROS). NADPH oxidase (NOX) is an enzyme
family that has the physiological function to produce ROS. NOX2 and NOX4 overexpression is associated with aggravated ischemic
injury, while NOX2/4-deficient mice had reduced stroke size. Dysregulation of matrix metalloproteinases (MMPs) contributes to
tissue damage. The active form of vitamin D3 expresses neuroprotective, immunomodulatory, and anti-inflammatory effects in
the CNS. The present study examines the effects of the vitamin D3 pretreatment on the oxidative stress parameters and the
expression of NOX subunits, MMP9, microglial marker Iba1, and vitamin D receptor (VDR), in the cortex and hippocampus of
Mongolian gerbils subjected to ten minutes of global cerebral ischemia, followed by 24 hours of reperfusion. The ischemia/
reperfusion procedure has induced oxidative stress, changes in the expression of NOX2 subunits and MMP9 in the brain, and
increased MMP9 activity in the serum of experimental animals. Pretreatment with vitamin D3 was especially effective on NOX2
subunits, MMP9, and the level of malondialdehyde and superoxide anion. These results outline the significance of the NOX and
MMP9 investigation in brain ischemia and the importance of adequate vitamin D supplementation in ameliorating the injury
caused by I/R.
1. Introduction
Cerebral ischemia is caused by various disorders, such as
myocardial infarction, stroke, or peripheral vascular disease
[1]. These diseases are the most common causes of mortality
and morbidity worldwide and represent a significant social
and economic burden [2, 3].
Decreased blood flow disturbs homeostasis of the brain
cells and causes noncontrolled formation of reactive oxygen
species (ROS). ROS can be derived from different sources,
including mitochondria, xanthine oxidase, uncoupled nitric
oxide synthase (NOS), and cyclooxygenase [4]. All of these
enzymes produce ROS as a by-product. However, recently
the enzyme family of NADPH oxidase (NOX), with the
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single known function of producing ROS, has been recog-
nized as an important source of free radicals in the ischemic
brain [4]. The NOX enzymes play essential roles in many
physiological processes including functioning of the brain,
immune system, vasculature, and signal transduction [4, 5].
Seven transmembrane NOX family members (NOX1–5 and
Duox1/2) transport electrons across biological membranes
to reduce oxygen to superoxide anion (O2
·−). NOX2 is the
most widely distributed among NOX isoforms, and it is
composed of two membrane subunits (gp91phox (referred as
NOX2) and gp22phox) and four cytosolic subunits (p47phox,
gp67phox, gp40phox, and Rac) [5]. NOX2 expression is present
in the different cells in the central nervous system (CNS)
including microglia [6], neurons [7, 8], and astrocytes [9].
Besides NOX2, the attention has recently been brought to
NOX4 that represents the most common isoform in the vas-
cular network, especially in the central nervous system [10].
NOX4 shares 39% similarity with NOX2 and requires only
p22 subunits [11] for ROS production. The expression of
the NOX is changed in the neurodegenerative diseases, aging,
seizures, and ischemic stroke [11]. To date, NOX2 and NOX4
isoforms are the most implicated to contribute to ROS
generation and pathology following cerebral ischemia [5].
An increase in NOX2 activity and expression has
repeatedly been found in different rodent models of stroke
[5, 11, 12]. The overexpression of NOX2 and NOX4 after
stroke has been associated with aggravated ischemic injury,
and the stroke size was reduced in NOX2- and NOX4-
deficient mice [4, 13].
Investigations in patients have also demonstrated
involvement of NOX in stroke pathophysiology [14]
although the patient sample size was small. Hence, these
NOX isoforms represent a potential therapeutic target. Many
NOX inhibitors have been proposed; however, the ideal one
has not been found so far due to the lack of selectivity, favor-
able toxicity, and bioavailability [15, 16].
Cerebral ischemia also leads to deregulation of matrix
metalloproteinases 2 and 9 (MMP) [17] causing matrix deg-
radation, blood-brain barrier (BBB) disruption, hemorrhage,
and brain edema [18, 19]. Park et al. [20] have shown that the
activity of MMP9 in serum reflects the activity of MMP9 in
the brain. In acute stroke, higher serum MMP9 levels are
found to correlate with infarct volume, disease severity, late
hemorrhage, mortality, and major disability [21–24]. How-
ever, MMP-targeted inhibitors that are not strictly specific
showed insufficient clinical benefits [25, 26]. Findings that
MMP9 activity and expression correspond to the increased
expression of NOX2 [27] offer the opportunity to regulate
MMP9 by inhibiting NOX2.
In ischemic tissue, reperfusion is of utmost importance
but reintroducing of oxygen leads to even greater ROS
production and mitochondrial dysfunction [9]. The begin-
ning of the reperfusion period is a perfect time to inhibit
ROS production. Although the right inhibitors have not been
synthesized yet, adjuvant nutritional interventions following
brain ischemia or trauma that are safe, low cost, and accessi-
ble have given promising results [28–30]. Besides applying
vitamin treatment after brain ischemia, several studies have
demonstrated that vitamin supplementation of the subjects
with increased risk for brain ischemia could be beneficial
[31, 32]. Vitamin D3 is currently the focus of investigation
since it is effective in neuroprotection and immunomodula-
tion and in decreasing inflammation in the CNS [33–35].
Vitamin D3 exhibits effects in the body through the vitamin
D nuclear receptors (VDR) that are present in the brain both
in neurons and in glial cells [36, 37]. Inverse associations
between the serum levels of 25-hydroxyvitamin D3 and the
risk of hypertension, cerebrovascular, and cardiovascular
incidents have been demonstrated [31, 38]. Many observa-
tional studies are in favor of the hypotheses that vitamin
D3 supplementation could be protective against stroke [31].
However, only a few interventional studies are available,
and their results differ, probably due to methodological lim-
itations [31, 32]. Problems in these trials have included the
dosage of vitamin D3, individual variations in response to
vitamin D3 supplementation, and expression of the results
as an incidence of cardiovascular or cerebrovascular events
instead of addressing the severity of the outcome.
This study was designed to assess the effects of vitaminD3
pretreatment on the expression of neuronal marker NeuN,
subunits of NADPH oxidase, MMP9, and microglial marker
(Iba1), as well as on the oxidative stress parameters including
the levels of O2
·−, malondialdehyde (MDA), and reduced glu-
tathione (GSH) and the activities of glutathione peroxidase
(GPx), glutathione reductase (GR), superoxide dismutase
(SOD), and gamma-glutamylcysteine ligase (γGCL) in the
cortex and hippocampus of Mongolian gerbils subjected to
global cerebral ischemia followed by 24 hours of reperfusion
(I/R). The activity of MMP9 was measured in the serum.
The expression of VDR, as an indicator of vitamin D3 activ-
ity, was also measured in the investigated brain structures.
2. Method
2.1. Animals. Adult 8-week-old male Mongolian gerbils were
used in this study. The animals were housed individually in
wire hanging cages located within a temperature-controlled
animal vivariummaintained under 12 : 12 h light/dark sched-
ule. Food and water were available ad libitum. Animals were
treated in accordance with the NIH Guide for Care and Use
of Laboratory Animals (1985) and European Communities
Council Directive (86/609/EEC). All efforts were made to
minimize animal suffering and to reduce the number of
animals used.
2.2. Global Cerebral Ischemia. The gerbils were randomly
divided into three groups. Group I (n = 20) was sham-
operated animals, which underwent the same surgical
procedure without vessel occlusion (control), group II
(n = 20) was subjected to ischemia/reperfusion (I/R), and
group III (n = 20) was treated with vitamin D3 and then
subjected to I/R (VitD + I/R). Ischemia was provoked by
bilateral common carotid occlusion (BCAO) for 10 minutes.
At the end of the 10-minute occlusion period, the clips were
removed and the cerebral blood flow was recovered. Reperfu-
sion lasted for 24 hours, after which gerbils were dispatched
by decapitation. The procedure of BCAO and reperfusion is
done in accordance with Selakovic et al. [39]. 1,25-(OH)2
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vitamin D3 (Calcitriol, Abbott lab) was injected intraperito-
neally (i.p.) at a dose of 1μg/kg/day [40], during the 7 days
prior to ischemia. Sham-operated and I/R-subjected animals
were treated with i.p. injections of saline (NaCl 0.9%) in the
same time points with corresponding volumes.
2.3. Quantitative Western Blot Analysis. For Western blot
analysis, animals were sacrificed by rapid cervical dislocation
and decapitation without anesthesia. The brains were
removed, and the dorsolateral frontal cortex and hippocam-
pus were dissected. These brain regions were homogenized
in lysis buffer (50mM Tris-HCl (pH7.4), 150mM NaCl,
1% IGEPAL CA-630, 1mM phenylmethylsulphonyl fluoride
(Sigma-Aldrich, P7626), protease inhibitor cocktail (Sigma-
Aldrich, P8340), 200mM sodium orthovanadate (Sigma,
Germany), and 1M sodium fluoride (Merck, USA)) on ice
for 30min, followed by centrifugation (18,000g for 15min
at 4°C), and the supernatants were collected. Protein concen-
trations were determined by the method of Bradford using
bovine serum albumin as a standard (Sigma). Equal amounts
of protein (50μg) from each sample were separated by SDS-
PAGE on 10% and 12% gels and transferred to nitrocellulose
membranes (Bio-Rad, Hercules, CA). Membranes were
blocked at room temperature for 1 hour in 5% nonfat dry
milk in Tris-buffered saline/0.1% Tween 20 (TBST). The
following primary antibodies were used in this study: mouse
polyclonal NeuN (1 : 1000, Millipore, Germany), mouse
polyclonal 91-phox (1 : 500, Santa Cruz, CA), rabbit polyclonal
p22-phox (1 : 500, Santa Cruz, CA), rabbit polyclonal p47-phox
(1 : 500, Santa Cruz, CA), rabbit polyclonal p67-phox (1 : 500,
Santa Cruz, CA), rabbit monoclonal NOX4 (1 : 5000, Abcam,
UK), rabbit polyclonal VDR (1 : 1000, Abcam, UK), goat
polyclonal anti-Iba1 (1 : 250, Abcam, UK), and rabbit poly-
clonal anti-MMP9 (1 : 1000, Sigma-Aldrich, Germany). After
incubation with primary antibodies, the membranes were
incubated with the HRP-labeled secondary anti-goat anti-
body (1 : 2000, Southern Biotech, USA), anti-rabbit antibody
(1 : 2000, Southern Biotech, USA), or anti-mouse antibody
(1 : 2000, Southern Biotech, USA) in TBST for 1 hour at room
temperature. Five subsequent washes with 0.1% TBST were
performed between each step. All membranes were stripped
and reprobed with anti-actin antibodies (1 : 10000, mouse
monoclonal, Sigma, USA). The signal was detected by
enhanced chemiluminescence and subsequent exposure on
an X-ray film. Western blot was scanned, and densitometric
analysis was performed using ImageQuant 5.2.
2.4. Immunohistochemistry. Brains were fixated in 4%
formaldehyde solution for 24 h at 4°C followed by sucrose
infiltration for 2 days at 4°C (30% sucrose in 0.1M phosphate
buffer), frozen by immersion in 2-methyl-butane (Sigma-
Aldrich, USA), and precooled and stored at −80°C until
cutting. Serial transverse sections (30μm thick) were cut on
a cryostat (Leica Instruments, Nußloch, Germany). Brain
sections were rehydrated and treated with citrate buffer
(pH6.0) in the microwave for antigen retrieval. Endogenous
peroxidase activity was blocked with 3% H2O2, and non-
specific labeling was blocked by a commercial protein
block (Vector, UK). Slices were incubated with primary
antibodies—mouse polyclonal NeuN (1 : 1000, Millipore,
Germany), rabbit monoclonal gp91phox (1 : 100, Abcam,
UK), rabbit monoclonal p22phox (1 : 300, Abcam), and goat
polyclonal anti-Iba1 (1 : 250, Abcam, UK)—overnight at
room temperature. Labeling was performed using a biotin-
conjugated secondary antibody, followed by streptavidin-
HRP, and visualization was done with 3,3′-diaminobenzidine
(DAB) chromogen (all components from the Vectastain
ABC HRP Kit, PK-4002, Vector, UK). Finally, the sections
were dehydrated and mounted with DPX (Sigma-Aldrich).
Pictures were taken using an Olympus BX41 microscope
with an Olympus C5060-ADU wide-zoom digital camera.
NeuN-positive cells were manually quantified using ImageJ
software. We have counted cell from each side, left and right,
in both structures. From each animal, six randomly selected
sections of the cortex and hippocampus per side were consid-
ered for counting at 400x magnification.
2.5. Gel Zymography. Serums from all experimental groups
were collected during decapitation. For gelatin zymography,
serums were diluted in 200 g/L sucrose to prepare the samples
as described inDragutinović et al. [41]. Equal amounts of pro-
teins were separated in nonreducing conditions on 7.5% SDS-
PAGE gel copolymerized with 0.01 g/L gelatin. Gels were
washed for 45min in 2.5% Triton X-100 to remove SDS and
incubated for 60 hours in 0.1mol/L glycine, 50mmol/L
Tris-HCl, 5mmol/L CaCl2, 1μmol/L ZnCl2, and 0.5mol/L
NaCl (pH8.3) at 37°C. Gels were then stained with 0.1% Coo-
massie blue G-250 for 2 hours and distained with 5% acetic
acid until white proteolytic bands appeared on the blue back-
ground. Wet zymograms were digitized using a scanner, and
gelatinolytic activity was quantified with ImageQuant 5.2.
2.6. Brain Preparation for Biochemical Measurements. The
dorsolateral frontal cortex and hippocampus were dissected,
and the crude synaptosomal fraction was prepared according
to the method of Whittaker and Barker [42]. Using a spectro-
photometric assay, reduced glutathione content [43], MDA
content [44], superoxide anion (O2
·−) levels [45], activity of
antioxidative enzymes (superoxide dismutase (SOD), gluta-
thione peroxidase (GPx), and glutathione reductase (GR))
[46–48], γGCL activity [49], and protein concentration [50]
were measured.
2.7. Transmission Electron Microscopy (TEM). For transmis-
sion electron microscopy, fixed brain samples were sliced
using a microslicer and fixed in 3% solution of glutaralde-
hyde (Merck, Darmstadt, Germany) in 0.1M cacodylate
buffer (pH7.4) (Merck, Darmstadt, Germany) overnight
at +40°C. Following osmification, pellets were dehydrated
in an ethanol gradient (Galenikaad, Serbia), cleared in pro-
pylene oxide (Merck, Germany), and then embedded in
Epon (Merck, Germany). Semithin sections were cut using
a diamond knife on a Leica Ultracut UCT EM FCS ultrami-
crotome (Leica Microsystems, Austria), stained with tolui-
dine blue, and analyzed by an Olympus BX41 light
microscope (Olympus, Japan). All the slides were photodo-
cumented with an Olympus C-5060 ADU wide-zoom
camera and the Olympus DP-soft Image Analyzer program
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(Olympus GmbH, Germany). The ultrathin sections from
chosen representative areas were cut with the same ultrami-
crotome, collected on copper grids, and stained with uranyl
acetate and lead citrate (SERVA Electrophoresis, Germany).
The sections were examined by FEI Morgagni 268D trans-
mission electron microscopy (FEI Europe, Netherlands)
and photographed with a Mega View III Soft Imaging System
digital camera (Olympus Soft Imaging Solutions, Germany).
2.8. Statistical Analysis. The Kolmogorov-Smirnov test has
been used to determine normality of the distribution of the
numerical values, and Levene’s test to test equality of vari-
ances between samples. The results are expressed as the
mean± standard error (SE) and were analyzed using the
one-way ANOVA with the Fisher post hoc test. The differ-
ences were considered to be significant at values of p < 0 05.
3. Results
3.1. I/R Procedure and Vitamin D3 Pretreatment Did Not
Change the Expression of NeuN, but Transmission Electron
Microscopy Revealed Subtle Subcellular Changes. Western
blot analyses showed unchanged expression of neuronal
marker (NeuN) among groups in both structures
(Figure 1(a)). Immunohistochemistry has confirmed these
results. Numerous NeuN-positive cells were found both in
the cortex and in the hippocampus (Figure 1(b)), and quan-
tification of NeuN-positive cells has shown the absence of a
significant difference in cell number among experimental
groups in both structures (Figure 1(c)). However, transmis-
sion electron microscopy (Figure 1(d)) revealed subtle sub-
cellular changes in the form of accumulation of transport
vesicles and rupture of the late endosome membrane in the
cells of animals subjected to I/R. These changes were less
prominent in the brain of the gerbils treated with vitamin
D3 before I/R.
3.2. Vitamin D3 Pretreatment Has Reversed Changes of the
Expression of Membrane NADPH Oxidase Subunits Caused
by I/R. The I/R procedure was followed by increased expres-
sion of gp91phox (Figure 2(a)) and p22phox (Figure 2(b)) in
both investigated brain structures. The expression of p47phox
was decreased (Figure 2(d)) in the cortex while the expres-
sion of NOX4 (Figure 2(c)) was decreased in the hippocam-
pus with respect to the control group. I/R did not cause any
change in the expression of p67phox (Figure 2(e)). Supple-
mentation with vitamin D3 prior to I/R has significantly
decreased expression of gp91phox and p47phox in the cortex
and hippocampus with respect to I/R, and in the hippocam-
pus, expression of these subunits was also significantly
decreased with respect to controls. Furthermore, in the
VitD + I/R group, expression of p22phox in the hippocampus
was decreased with respect to I/R and controls, while the
expression of p22phox in the cortex and the expression of
p67phox in the hippocampus were increased with respect to
the I/R group and controls. Vitamin D3 caused normalization
of NOX4 expression in the hippocampus.
Immunohistochemical staining of gp91phox in regions of
the retrosplenial agranular (RSA) cortex and retrosplenial
granular (RSG) cortex showed gp91phox-positive cells in
all cortex layers in all investigated groups. In control and
VitD + I/R groups (Figures 3(a), A and 3(a), C), the cell
membrane reacted to staining, with a weaker reaction in
the cytoplasm. In the I/R group (Figure 3(a), B), cells showed
an extensively coloredmembrane and a strong reaction in the
cytoplasm. Gp91phox-positive cells were also found in the hip-
pocampus (CA1, CA2/3, and dentate gyrus (DG)). As in the
cortex, the stronger staining was noticed in the I/R group
(Figure 3(a), E) compared to control and VitD + I/R groups
(Figures 3(a), D and 3(a), F).
Immunohistochemical staining on p22phox in regions of
the RSA cortex and RSG cortex in all experimental groups
revealed a regular, dense network mainly composed of
parallel-arranged apical dendrites of pyramidal neurons, as
well as of some impregnated pyramidal perikarya. Immuno-
reactivity was stronger in the I/R group (Figures 3(b), B and
3(b), E) and even more prominent in the VitD + I/R group
(Figures 3(b), C and 3(b), F). Interestingly, the CA2/3 hippo-
campal region responded to experimental conditions more
than the CA1 and DG regions. In the control group, a net-
work of long impregnated dendrites and sporadic perikarya
can be seen (Figure 3(b), G). Numerous and prominent stain-
ings of cell bodies are observed in the I/R group (Figure 3(b),
H). Vitamin D3 pretreatment decreased immunoreactivity
with respect to the control group (Figure 3(b), I).
3.3. Expression of Iba1 Was Unchanged in All Experimental
Groups. Expression of Iba1 (Figure 4(a)) was unchanged in
the cortex and hippocampus in experimental groups com-
pared to control. Immunohistochemistry revealed ramified
morphology of Iba1-positive cells in all investigated groups
(Figure 4(b)).
3.4. I/R Caused a Significant Increase in the Expression and
Activity of MMP9, and Vitamin D3 Normalized This
Change. Changes of the expression of MMP9 were seen only
in the cortex. Expression of this protein was increased in the
I/R group compared to controls while vitamin D3 attenuated
this change (Figure 5(a)).
The activity of MMP9 (Figure 5(b)) in serum was
increased in the I/R group compared to control. Vitamin
D3 has decreased MMP9 activity in serum with respect to
the I/R group.
3.5. Expression of VDR. Vitamin D3 supplementation was
followed by a significant increase in VDR expression with
respect to the I/R group in both structures (Figure 6).
3.6. Vitamin D3 Exhibits No Effects on GSH Levels and
Enzymes Involved in Its Metabolism. The level of GSH was
decreased (Table 1) in all investigated brain structures after
I/R; pretreatment with vitamin D3 did not have effects on this
change. Among the enzymes involved in glutathione metab-
olism, the GR activity (Table 2) was increased after I/R and
vitamin D3 pretreatment. The activity of GPx and γGCL
(Table 2) remained unchanged among experimental groups
in the investigated brain structures.
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3.7. Lipid Peroxidation Expressed by the Levels of MDA Was
Increased in the Cortex and Hippocampus after I/R, and
Vitamin D3 Pretreatment Has Protective Effects. Measure-
ment of MDA levels (Table 1) revealed an increase in
lipid peroxidation in the cortex and hippocampus of the
I/R group compared to control, and vitamin D3 reversed
these changes.
3.8. Superoxide Anion Production Was Increased in All Brain
Structures after I/R, and Vitamin D3 Attenuated These
Effects. The content of O2
·− (Table 1) was increased in the
investigated brain structures of the I/R group compared to
control. Vitamin D3 attenuated these changes completely in
the cortex and hippocampus.
3.9. Total Activity of SOD Was Increased in the Investigated
Brain Structures after I/R. The total activity of SOD
(Table 2) was increased in the cortex and hippocampus of
the I/R group compared to control. In the VitD + I/R group,
the total activity of SOD (Table 2) remained increased with
respect to controls, and this increase was statistically signifi-
cant in the hippocampus.
4. Discussion
This study has demonstrated that ten minutes of global tran-
sient cerebral ischemia followed by 24 hours of reperfusion
results in oxidative stress and changes in the expression of
NOX2 that are probably not derived in microglia. Also, the
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Figure 1: (a) Expression of NeuN. Group I (n = 6) was sham-operated animals, which underwent the same surgical procedure without
vessel occlusion (control), group II (n = 6) was subjected to ischemia/reperfusion (I/R), and group III (n = 5) was treated with vitamin
D3 and then subjected to I/R (VitD + I/R). All experiments were performed in synaptosomal fraction in different brain structures.
(b) Immunohistochemical staining of NeuN-positive cells in gerbil brain slices. Magnification of the upper and lower images is 100x and 200x,
respectively. (c) Number of cells per field in group I (sham-operated animals), group II (subjected to ischemia/reperfusion (I/R)), and group
III (treated with vitamin D3 and then subjected to I/R (VitD + I/R)). (d) The TEM analysis of neurons. (Left) The neuronal cell from the
control group shows late endosomes (LE) with an intact membrane, ribosomes (R), and mitochondria (M) (bar = 1μm). (Middle) The
neuron after I/R shows late endosome with membrane rupture, accumulation of transport vesicles (TV), and more ribosomes
(bar = 0.5 μm). (Right) The neuron cell after the VitD + I/R procedure shows intact endosome, some vesicles, Golgi apparatus (G), and
rough endoplasmic reticulum (ER) (bar = 1μm).
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applied I/R procedure caused an increase in MMP9 expres-
sion in the brain and activity in the serum. More impor-
tantly, this study has demonstrated that vitamin D3
supplementation prior to I/R decreases oxidative stress
and NOX2 and MMP9 expressions in the gerbil’s brain.
Increased expression of the VDR in vitamin D3-pretreated
animals subjected to I/R indicates that supplementation is
effective even the starting levels of vitamin D.
Although several previous studies have demonstrated the
absence of changes in the number and morphology of brain
cells 24 hours after brain ischemia [51, 52], subtle biochemi-
cal changes that have a potential to be a therapeutic target
occur early after ischemia and are present in the first 24 hours
of reperfusion [39, 40, 52].
In our study, 10 minutes of global brain ischemia
followed by 24 hours of reperfusion did not change the
expression of the neuronal marker NeuN and the number
or morphology of neurons. However, transmission electron
microscopy revealed subtle subcellular changes in the form
of accumulation of transport vesicles and rupture of the late
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Figure 2: Expression of NADPH oxidase subunits: (a) gp91phox, (b) p22phox, (c) NOX4, (d) p47phox, and (e) p67phox. Group I (n = 6) was
sham-operated animals, which underwent the same surgical procedure without vessel occlusion (control), group II (n = 6) was subjected to
ischemia/reperfusion (I/R), and group III (n = 5) was treated with vitamin D3 and then subjected to I/R (VitD + I/R). All experiments were
performed in synaptosomal fraction in different brain structures. Results are presented as mean± SE. ∗p < 0 05 versus control, ∗∗p < 0 01
versus control, §p < 0 05 versus I/R, and §§p < 0 01 versus I/R.
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endosome membrane in the cells of animals subjected to I/R.
These changes were less prominent in the brain of the gerbils
treated with vitamin D3 before I/R. Our results are in agree-
ment with the results of the investigation of Cao et al. [51]
who have revealed the absence of ischemic lesions one day
after 15 minutes of brainstem ischemia in Mongolian gerbils.
These authors have found ischemic lesions immediately after
ischemia that disappeared after one day and reappeared 3
days after reperfusion. Furthermore, the latest study of Yuan
et al. [52] has also demonstrated that 20 minutes of transient
global brain ischemia leads to delayed neuronal death that is
present after 72 h of reperfusion. These scientists have also
shown that although neuron morphology was intact 24 hours
after reperfusion, subcellular changes in the form of accumu-
lation of damaged Golgi, transport vesicles, and late endo-
somes and ribosomes were present.
Several studies have suggested the role of NOX2 as a
source of ROS in I/R [5, 53–55]. In our study, the animals
subjected to I/R had increased expression of two investigated
membrane subunits of NOX2 (gp91phox and p22phox) and
increased levels of O2
·− and MDA both in the cortex and in
the hippocampus. However, changes of the expression of reg-
ulatory cytosolic subunits (p47phox and p67phox) differ in the
investigated brain structures. In the cortex, p47phox was
decreased probably indicating an attempt to establish a bal-
ance, while expression of p67phox was not changed. Our
results are in accordance with the results of previous studies.
Yoshioka et al. [56] have also found upregulation of the
membrane subunit gp91phox and the absence of the changes
in the expression of regulatory subunits p47phox and p67phox
twenty-four hours after 22 minutes of global cerebral ische-
mia in the striatum of C57BL/6 mice. However, these authors
have demonstrated the dynamic of the changes in the expres-
sion of cytosolic NOX2 subunits, and upregulation was
found in the early (3–6 hours) and late phase (72 hours) after
the ischemic procedure [56]. The authors have suggested that
NOX activation arose in medium spiny neurons and endo-
thelial cells at the early phase and in reactive microglia at
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Figure 3: Immunohistochemical staining of gp91phox and p22phox in gerbil brain slices. Magnification of images for (a) from A–F is 200×, for
(b) from A–C is 40×, and for (b) from D–I is 100×.
7Oxidative Medicine and Cellular Longevity
the late phase. Additionally, increased p47phox immunoreac-
tivity was demonstrated in the hippocampus and striatum of
the same mice strain 72 hours after 30 minutes of global cere-
bral ischemia [57]. Supplementation with vitamin D3 prior
to ischemia, in our study, was followed by reduced expression
of gp91phox and p47phox subunits in both the cortex and hip-
pocampus, increased expression of p22phox in the cortex and
decreased expression of this subunit in the hippocampus, and
increased expression of p67phox in the hippocampus. Levels
of O2
·− and MDA were decreased as well, suggesting that
NOX2 could be an important source of free radicals. The
study of Dong et al. [58] has demonstrated reducing effects
of vitamin D3 on the expression of NOX2 and NOX4 and
the levels of ROS in the models of renovascular hypertension
both in vivo and in vitro. Similarly, Hirata et al. [59] have
shown decreased expression of p22phox after the treatment
with calcitriol analog 22-oxacalcitriol in an animal model of
diabetes mellitus 2, as well as in human coronary artery
endothelial cells cultured in high-glucose medium. Vitamin
D3 treatment of human promyelocytic NB4 cells has
decreased expression of the NOX2 components (p22phox,
p91phox, p47phox, and p67phox) leading to undetectable levels
of gp91phox and p22phox proteins and the low level of p47phox
and p67phox [60]. In our study, vitamin D3 has shown
structure-specific effects on p22phox and p67phox.
Although NOX4 has been implicated as a source of
free radicals in transit or permanent focal brain ischemia
[4, 14, 61], our study has demonstrated that global transit
ischemia lasting for 10 minutes followed by 24 hours of
reperfusion was followed with either baseline (cortex) or
decreased (hippocampus) expression of NOX4. These results
indicate that NOX4 is not an important source of free
radicals in this phase of reperfusion. These results are in
accordance with the findings of Nishimura et al. [61] who
have reported upregulation of NOX4 in brain pericyte
culture after exposition to 1% O2 hypoxia for over 24 hours
and prompted downregulation by reoxygenation with
returning to baseline levels within 24 hours. Pretreatment
with vitamin D3 in our study kept NOX4 at the baseline level
in both investigated brain structures, and this could be of
great importance, since it is shown that NOX4 constitutively
produces small amounts of H2O2 affecting vascular dilatation
[62]. Additionally, endothelial NOX4 is involved in angio-
genesis and subsequent healing process after tissue damage
[61]. To the best of our knowledge, there are no results of
the effects of global cerebral ischemia on the NOX4. Further-
more, we have found a significant increase in MMP9 expres-
sion in the cortex, and this change has been prevented by the
pretreatment with vitamin D3. A recent study of Tang et al.
[63] has suggested that NOX2 is a major precipitating factor
for the increased MMP9 expression in ischemic brain tissue,
since 90min of middle cerebral artery occlusion followed by
22.5 h of reperfusion has increased expressions of both
NOX2 and MMP9, while inhibition of NOX2 with apocynin
reduced the increase in MMP9. However, we have found
increased expressions of both NOX2 and MMP9 in the cor-
tex while in the hippocampus, only NOX2 was elevated.
Nishimura et al. [61] have found that NOX4 is responsible
for MMP9 activation. Indeed, we have observed a similar
expression profile of NOX4 and MMP9 in the hippocampus.
It is possible that MMP9 in specific brain regions responds to
different signals. The findings of different MMP9 expression
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Figure 4: (a) Expression of Iba1. Group I (n = 6) was sham-operated animals, which underwent the same surgical procedure without vessel
occlusion (control), group II (n = 6) was subjected to ischemia/reperfusion (I/R), and group III (n = 5) was treated with vitamin D3 and then
subjected to I/R (VitD + I/R). All experiments were performed in synaptosomal fraction in different brain structures. Results are presented as
mean± SE. (b) Immunohistochemical staining of Iba1-positive cells in gerbil brain slices. Magnification of images is 200x.
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in the cortex and hippocampus could also be explained by the
dynamic of changes after brain ischemia. It is possible that
MMP9 expression would be increased in the hippocampus
after a longer period of reperfusion. Besides that NOX
influenced the expression of MMPs, it is shown that once-
activated microglia release MMPs [64]. Our study has
demonstrated ramified morphology of microglia and the
absence of changes in the expression of microglial marker
Iba1 after the applied I/R procedure. These findings are
indicative of the presence of inactivated, resting microglia
and suggest other sources of MMP9. In our investigation,
MMP9 was also increased in the serum of animals subjected
to the I/R procedure and decreased in animals pretreated
with vitaminD3. Previous studies have reported that elevated
plasma levels of MMP9 correlate with poor neurological
outcomes during acute stages of both ischemic stroke and
hemorrhagic stroke [19, 23], while Park et al. [20] have
demonstrated that the total MMP9 activity in plasma highly
correlates with the activity in the brain homogenate. Timms
et al. [65] have reported an abnormal increase in circulating
MMP9 in subjects with vitamin D3 deficiency. Our study
supports the usefulness of MMP9 as a biomarker and
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Figure 5: Expression of MMP9. Group I (n = 6) was sham-operated animals, which underwent the same surgical procedure without vessel
occlusion (control), group II (n = 6) was subjected to ischemia/reperfusion (I/R), and group III (n = 5) was treated with vitamin D3 and
then subjected to I/R (VitD + I/R). All experiments were performed in synaptosomal fraction in different brain structures. (b) Activity of
MMP9 in animal serum. Results are presented as mean± SE. ∗∗p < 0 01 versus control, §p < 0 05 versus I/R, and §§p < 0 01 versus I/R.
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indicates the effectiveness of vitamin D3 in reversion of
changes of MMP9 caused by I/R. MMPs have been pursued
as potential therapeutic targets, and MMP inhibitors were
found to be effective in reducing infarct volumes in the ani-
mal models of focal cerebral ischemia when administered
early during acute ischemic stroke [18]. On the other hand,
a biphasic role of MMPs after brain injury has been sug-
gested. In the acute phase, they are found to be deleterious,
but in delayed remodeling and recovery, they are potentially
beneficial, and blocking MMPs in this phase may even
worsen outcomes [18].
Investigations of the antioxidative defense systems in our
study have revealed a significant increase in the total SOD
activity and a significant decrease in the levels of GSH in
investigated brain regions. However, GPx, GR, γGCL activi-
ties were unchanged. Previous studies have shown that
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Figure 6: Expression of VDR. Group I (n = 6) was sham-operated animals, which underwent the same surgical procedure without vessel
occlusion (control), group II (n = 6) was subjected to ischemia/reperfusion (I/R), and group III (n = 5) was treated with vitamin D3 and
then subjected to I/R (VitD + I/R). All experiments were performed in synaptosomal fraction in different brain structures. Results are
presented as mean± SE. §p < 0 05 versus I/R and §§p < 0 01 versus I/R.
Table 1: Levels of GSH, MDA, and O2
·− in the synaptosomal fraction of different brain structures in group I (n = 6) (sham-operated animals,
which underwent the same surgical procedure without vessel occlusion (control)), group II (n = 6) (subjected to ischemia/reperfusion (I/R)),
and group III (n = 5) (treated with vitamin D3 prior to I/R (VitD3 + I/R).
Brain structure
Cortex Hippocampus
Parameter Group
GSH (mmol/mg protein)
Ctrl 12.77± 0.59 12.06± 0.90
I/R 7.07± 1.03∗ 8.03± 1.14∗
VitD3 + I/R 4.13± 0.62∗§ 6.80± 1.20∗
MDA (mmol/mg protein)
Ctrl 35.22± 1.63 29.68± 0.64
I/R 51.33± 5.73∗ 38.24± 2.61
VitD3 + I/R 39.51± 4.19§ 32.19± 2.77§
O2
·− (nM/min/mg protein)
Ctrl 8.09± 0.34 9.82± 0.25
I/R 10.88± 0.29∗∗ 11.47± 0.34∗∗
VitD3 + I/R 8.93± 0.33§§ 10.19± 0.28§§
Results are presented as mean ± SE. ∗p < 0 05 versus control, ∗∗p < 0 01 versus control, §p < 0 05 versus I/R, and §§p < 0 01 versus I/R.
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SOD represents the main endogenous protective system
against an excitotoxic and ischemic/hypoxic lesion [66]
and that the lower GSH levels are indicative of the greater
injury after I/R [39]. Vitamin D3 did not prevent a decrease
in GSH caused by the I/R procedure. We have found
increased SOD activity in the investigated brain structures
in the I/R group compared to control, implying the
attempts of antioxidant mechanisms to respond to high oxi-
dative demands. However, the levels of the O2
·− and MDA
were significantly increased with respect to controls. Both
findings indicate the presence of oxidative stress. In I/R ani-
mals pretreated with vitamin D3, the levels of O2
·− and
MDA were normalized while the activity of SOD was still
statistically significantly increased in the hippocampus.
These findings indicate protective effects of vitamin D3
against oxidative stress.
Antioxidant capacity of vitamin D3 has been shown in
the investigations on the animal model of nonalcoholic fatty
liver disease [67]. The authors have applied intraperitoneal
injection of 1,25-(OH)2 vitamin D3, twice per week, for 16
weeks and have demonstrated protective effects against oxi-
dative stress in the liver. It is suggested that antioxidant
capacity of vitamin D3 lays in the induction of NRF2 nuclear
translocation factor, upregulation of the expression of genes
encoding antioxidant enzymes [67], and inhibition of nuclear
factor-kappa B, NOX2, and NOX4 genes [36, 68].
Our findings that vitamin D3 decreases gp91phox and
p47phox expression and decreases ROS formation and espe-
cially the effects of vitamin D3 supplementation on the
increase in the VDR expression support the idea that vitamin
D3 supplementation can be recommended to all subjects par-
ticularly to those with the high risk for cardiovascular and
cerebrovascular disorders, even when they have normal
serum levels of 25-OH vitamin D.
Although our investigation has revealed the effects of the
I/R procedure and vitamin D3 pretreatment on the NOX2
and NOX4 subunits, MMP9, and parameters of oxidative
stress, there are several limitations of the study. First, there
is a need to test the dynamic of changes of selected parame-
ters after different durations of ischemia and reperfusion.
Moreover, we have tested the effects of vitamin D3 pretreat-
ment in animals that were not vitamin D deficient. It would
be necessary to investigate the effects of vitamin D3 supple-
mentation on I/R injury in the group of animals on a vitamin
D3-deficient diet. Additionally, treating the animals with
vitamin D3 immediately after the brain ischemic procedure
would provide an insight into wholesomeness of vitamin
D3 application early after cerebrovascular incidents. Finally,
the different protocols and given doses should be tested.
5. Conclusions
Ten minutes of global cerebral ischemia followed by 24 hours
of reperfusion induces changes in the expression of NOX2
subunits and MMP9 and changes of the oxidative stress
parameters in the brain, as well as the increase in MMP9
activity in the serum of experimental animals. These results
emphasize the role of NOX2 andMMP9 in the pathophysiol-
ogy of brain ischemia. Pretreatment with vitamin D3,
followed by the increase in VDR expression, is especially
effective on the changes of the membrane NOX2 subunits,
MMP9, and the levels of MDA and O2
·−. We are stressing
the significance of vitamin D3 supplementation in ameliorat-
ing the injury caused by ischemia/reperfusion.
Abbreviations
ADP: Adenosine diphosphate
ATP: Adenosine triphosphate
BBB: Blood-brain barrier
BCAO: Both common carotid artery occlusion
CNS: Central nervous system
Table 2: Activities of the GPx, GR, γGCL, and total SOD in the synaptosomal fraction of different brain structures in Group I (n = 6)
(sham-operated animals, which underwent the same surgical procedure without vessel occlusion (control)), group II (n = 6) (subjected
to ischemia/reperfusion (I/R)), and group III (n = 5) (treated with vitamin D3 prior to I/R (VitD3 + I/R).
Brain structure
Cortex Hippocampus
Parameter Group
GPx (U/mg protein)
Ctrl 29.34± 4.20 38.91± 3.62
I/R 31.40± 3.91 27.85± 5.22
VitD + I/R 31.60± 1.78 26.25± 4.79
GR (U/mg protein)
Ctrl 15.76± 3.1 6.68± 1.1
I/R 28.58± 5.11∗ 28.43± 5.26∗∗
VitD + I/R 38.19± 4.11 19.43± 4.83
γGCL (U/mg protein)
Ctrl 15.76± 0.11 6.68± 0.43
I/R 28.58± 0.10∗ 28.43± 0.12∗
VitD + I/R 38.19± 0.08∗ 19.43± 0.29
SOD (U/mg protein)
Ctrl 128.61± 3.11 129.52± 1.11
I/R 183.36± 5.11∗∗ 192.26± 5.26∗∗
VitD + I/R 145.04± 4.05 184.37± 4.83∗
Results are presented as mean ± SE. ∗p < 0 05 versus control and ∗∗p < 0 01 versus control.
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DTNB: Dithionitrobenzoic acid
DUOX 2: Dual oxidase 2
GD: Gyrus dentatus
γGCL: Gamma-glutamylcysteine ligase
GPx: Glutathione peroxidase
GR: Glutathione reductase
GSH: Glutathione
Iba1: Ionized calcium-binding adapter molecule 1
I/R: Ischemia reperfusion
MDA: Malondialdehyde
MMP: Matrix metalloproteinases
NADH: Nicotine adenine dinucleotide
NADPH: Nicotine adenine dinucleotide phosphate
NOS: Nitric oxide synthase
NOX: NADPH oxidase
RSA: Retrosplenial agranular cortex
RSG: Retrosplenial granular cortex
ROS: Reactive oxygen species
SDS: Sodium dodecyl sulfate
SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel
electrophoresis
SOD: Superoxide dismutase
SOD1: Copper-zinc superoxide dismutase
SOD2: Manganese superoxide dismutase
TBST: Tris-buffered solution/Tween 20
TIMP: Tissue inhibitor of metalloproteinase
VitD3: Vitamin D3 (1,25-dihydroxycholecalciferol).
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